国产辛伐他汀和阿昔莫司联合治疗高脂血症

目的 探讨联合应用国产辛伐他汀和阿昔莫司治疗混合性高脂血症的临床疗效及安全性.方法 共入选222例混合性高脂血症患者,随机分入辛伐他汀组(n=72)、阿昔莫司组(n=74)和联合治疗组(辛伐他汀 阿昔莫司,n=76).观察治疗前后主要血脂参数的变化幅度以及不良反应.结果 联合治疗组血脂参数变化幅度最显著,血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和甘油三酯(TG)均显著下降,而血清高密度脂蛋白胆固醇(HDLC)升高优于辛伐他汀组和阿昔莫司组(P＜0.01).结论 阿昔莫司组与小剂量辛伐他汀联合治疗可以更全面地改善混合性高脂血症患者的血脂异常.较单药治疗更有效.具有良好的安全性和耐受性.

The study of combination therapy with simvastin and acipimox for combined hyperlipidemia

Objective To evaluate the efficacy and safety of combination therapy with Chinese domestic simvastatin and acipimox in patients with combined hyperlipidemia. Methods A total of 222 patients with combined hyperlipidemia were randomly divided to two groups, one group received 10 mg simvastatin (n=72) or 0.75g acipimox (n=74), the other group received a combination of 10 mg simvastatin + 0.75 g acipimox(n=76) for 3 months. The lipid profiles, physical and laboratory investigations for adverse effects were assessed. Results Combination treatment was more effective in normalizing lipid profile than simvastatin or acipimax alone monotherapy. Serum TC, LDL-C, and TG were reduced by 29.8%, 37.6% and 57.7% respectively, while HDL-C was significantly increased by 23.5%(P<0.01). The improvement in TG and HDL-C in combination treatment was superior to acipimox or simvastatin alone. The success rate of TC, LDL-C and TG control in the combination therapy group was 51.3% , 55.3% and 61.8% respectively, with an overall success rate (all three together)of 44.7%, which was superior to either single drug given in this study. All treatments were well tolerated with no increase in adverse events for combination therapy. Conclusions The results of this study demonstrated that combination therapy with acipimox (0.75 g/d) and low-dose simvastatin (10 mg/d) is more effective than single drug therapy in patients with combined hyperlipidemia, and is generally safe and well tolerated.